Crinetics Pharmaceuticals Inc. Common Stock (CRNX)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first at business quality and staying power. Crinetics is a clinical-stage biotech with a lead candidate, Paltusotine, in Phase 3 for acromegaly and carcinoid syndrome, plus Atumelnant. That is a speculative, binary business, not a predictable consumer franchise; I cannot identify a durable moat from these figures. Financial health is mixed: debt is low at a D/E of 0.04, but the latest reported quarter, fiscal Q2 2026, showed revenue of $25.1 million against a net loss of $120.9 million, a -481.15% margin. Trailing free cash flow was -$425.2 million, a -10.5% FCF yield on the $4.1 billion market cap. FairStock calculations at the $84.95 close on 2026-09-02 show a P/E of -16.82, P/B of 7.54, ROE of -42.45%, ROCE of -26.28%, Piotroski score of 3/9, Altman Z-score of 17.73, and a 30/100 FairStock score. The low debt and high Altman number reduce immediate solvency worry, but the negative returns and heavy cash burn are the real issues. Valuation offers no Graham-style margin of safety: a $4.1 billion market cap rests on future clinical and commercial success, while the stock sits near the top of its $32.30-$85.01 52-week range. FairStock’s Lynch category is none because only 0 years of filed results are available and three are needed, so history is thin. Growth potential exists if Paltusotine succeeds, but I would require evidence of durable revenue and controlled cash burn before calling the business strong.

In plain English: Crinetics is a clinical-stage drug company working on oral treatments for rare hormone-related diseases. It is not profitable: in fiscal Q2 2026 it reported $25.1 million of revenue and a $120.9 million net loss. At $84.95, the stock looks expensive relative to its current profits and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-09-02 close · note generated 2026-10-28 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer